ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc

Bullboard Posts

Comment by jjwilsonon Oct 18, 2018 8:39am

56 Views

Post# 28825638

RE:RE:RE:RE:Dementia

My link didn't show up properly. I'll try again but if it doesn't work just search Amazon for "Jay Ingram Fatal Flaws" The book shows up with several different covers but they're all the same - just changed for various re-printing runs.

https://www.amazon.ca/s/ref=nb_sb_noss?url=search-alias%3Daps&field-keywords=Jay+Ingram+Fatal+Flaws

Fatal Flaws

Bullboard Posts

Mullen Group's Robust Case for Value, Part 1: Less-than-Truckload